U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics' experimental drug to treat advanced bladder cancer, about three months ahead of schedule.
from Reuters: Health News https://ift.tt/2Q2tzkn
via
IFTTT